49.34 0.00 (0.00%)
After hours: 4:45PM EDT
|Bid||49.01 x 1000|
|Ask||51.18 x 100|
|Day's Range||49.19 - 50.05|
|52 Week Range||48.25 - 68.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||0.35 (0.71%)|
|1y Target Est||68.36|
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Strata Skin Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free earnings report on DENTSPLY SIRONA Inc. (NASDAQ: XRAY ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding XRAY totaled $14.30 billion.
On April 6, 2018, Dentsply Sirona (XRAY) ended at a closing price of $49.02 per share. The stock declined by ~0.14% on the day. XRAY stock was trading at a 52-week high of $68.98 on November 28, 2017. However, the company’s 52-week low came on April 2, 2018, at $48.25. This recent stock price decline was triggered by negative investor sentiments for the company due to recent target price cuts by Wall Street analysts following downward revisions and modelling adjustments in the company’s fiscal 4Q17 earnings release on March 2 and the recent OraMetrix acquisition announcement.
Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years. This weak performance was due to the lower-than-expected synergies delivered after the merger of Dentsply International and Sirona Dental Systems in February 2016, which led to the formation of Dentsply Sirona. For more detail, read Inside Dentsply Sirona’s New Turnaround Plan.
Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.
On March 26, 2018, Dentsply Sirona (XRAY) announced the acquisition of OraMetrix, a Texas-based privately held company. The acquisition aims to expand the orthodontic treatment solutions that Dentsply Sirona offers.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding XRAY totaled $3.79 billion.
YORK, Pa., March 26, 2018-- DENTSPLY SIRONA Inc., The Dental Solutions Company™, today announced the signing of a definitive agreement to acquire OraMetrix, a leading industry provider of innovative 3- ...
In 2018, Dentsply Sirona (XRAY) is expected to register flat margins or a decline in EBIT (earnings before income and tax) margin. By comparison, peers Danaher (DHR), Zimmer Biomet Holdings (ZBH), and Integra Lifesciences (IART) registered operating margin growth of 16.5%, 10.3%, and 3.7%, respectively, in fiscal 2017. The company currently has an attractive margin profile and registered a gross margin of ~55% of the company’s total sales in 2017. As the company evaluated its impairment analysis results, it saw a significant impairment charge in 2017.
Dentsply Sirona (XRAY) reported its 2018 guidance during the company’s 4Q17 and fiscal 2017 earnings results release on March 2, 2018. For fiscal 2018, Dentsply Sirona has an adjusted EPS (earnings per share) guidance range of $2.70–$2.80, representing a growth rate of 8% to 11%. Dentsply Sirona expects to generate flat margins or a decline in its gross margin and operating margin due to currency headwinds, and the negative impact of the reductions in dealer equipment levels.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Dentsply Sirona (XRAY) plans to reinvest these savings and other available capital into company’s R&D (research & development) initiatives to accelerate innovation and sales and marketing strategies. Some of the key areas that the company is focused on include its CAD-CAM and implants businesses. Densply Sirona continues to see enormous potential in the company’s chairside dentistry and digital dentistry businesses.
Although Dentsply Sirona (XRAY) has given a disappointing performance recently, the company is still confident that it can gain a higher market share going forward. The company’s strategic growth plan consists of five key priorities meant to counteract the impact of the significant impairment charges it saw in 2017 (stemming from the merger of Dentsply International and Sirona Dental Systems in February 2016). Below, we’ll discuss why Dentsply Sirona is so confident that it can gain a higher market share in 2018 and 2019.
Dentsply Sirona (XRAY) has a new management team that is working toward a more successful integration, because the company delivered lower-than-expected synergies in 2017 (due to the merger of Dentsply International and Sirona Dental Systems in early 2016). The company has now put in place a new management team that has prioritized five key factors to focus on for the growth of the company (see the previous parts of this series). One of the company’s key priorities is to improve its operational growth through margin improvement.
Dentsply Sirona (XRAY) has delivered lower merger synergies than the company had estimated. It also took an impairment charge during 4Q17 in relation to merger synergies. For a turnaround after the merger of Dentsply International and Sirona Dental Technologies, Dentsply Sirona has made some leadership changes, as we discussed in the preceding parts of this series. The new leadership team has put in place a plan with five key priorities, and one of the biggest priority areas involves business growth going forward, which we’ll discuss in more detail below.
With the recent transition in leadership at Dentsply Sirona (XRAY), the new team has laid out a robust strategic growth plan. With the ongoing challenges in the integration process of Dentsply International and Sirona Dental Systems, the new management has put forth a priority of positioning itself as an integrated one global team.
In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17. The company had a two segment operational structure prior to 3Q17, but the new two-segment structure has some differences, which we’ll discuss below.
Starting in October 2017, Dentsply Sirona (XRAY) implemented a series of management changes with the aim of positioning the company as a stronger and more efficient organization and maintaining the company’s leadership position in dentistry. In October, the company accepted the resignations of Executive Chairman Bret W. Wise, CEO and Director Jeffrey T. Slovin, and President and COO (chief operating officer) Christopher T. Clark. Mark A. Thierer was appointed interim CEO, and Bob Size was appointed interim president and COO. Mark A. Thierer has around 30 years of healthcare industry experience and most recently served as the CEO of OptumRx.
While the MedTech fraternity is hopeful about the latest MedTech tax repeal, we would like to draw your attention to the slump in share price and net margin figures following the tax's abolition in 2015.